LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ:QURE), a arch gene analysis aggregation advancing transformative therapies for patients with astringent unmet medical needs, such as hemophilia B, Huntington’s ache and congestive affection failure, today appear the appraisement of its underwritten accessible alms of 5,000,000 of its accustomed shares at a accessible alms amount of $18.25 per share. The gross gain to uniQure from the offering, afore deducting the underwriting discounts and commissions and estimated alms costs payable by uniQure, are accepted to be $91,250,000. All accustomed shares to be awash in the alms are actuality awash by uniQure. In addition, uniQure has accepted to the underwriters a 30-day advantage to acquirement up to 750,000 added accustomed shares at the accessible alms price, beneath underwriting discounts and commissions. The alms is accepted to aing on or about October 27, 2017, accountable to the achievement of accepted closing conditions.
Leerink Partners and Evercore ISI are acting as collective book-running managers for the offering. Chardan is acting as beforehand administrator and H.C. Wainwright & Co. is acting as co-manager for the offering.
The balance declared aloft are actuality offered by uniQure pursuant to its shelf allotment account on Form S-3 (File No. 333-216701) filed with the Balance Exchange Commission (the “SEC”) on March 15, 2017, as adapted on May 15, 2017 and declared able by the SEC on May 26, 2017. A basic announcement supplement and accompanying announcement apropos to the alms was filed with the SEC and a final announcement supplement and the accompanying announcement apropos to this alms will be filed with the SEC. When available, copies of the final announcement supplement and the accompanying announcement apropos to the alms may be acquired from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by blast at (800) 808-7525 ext. 6132 or by email at [email protected]; and Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, or by blast at (888) 474-0200, or by email at [email protected] The basic announcement supplement and accompanying announcement is additionally available, and the final announcement supplement and accompanying announcement will be available, for chargeless on the SEC’s website at http://www.sec.gov.
This columnist absolution shall not aggregate an action to advertise or the address of an action to buy these securities, nor shall there be any auction of these securities, in any accompaniment or added administration in which such offer, address or auction would be actionable above-mentioned to allotment or accomplishment beneath the balance laws of any such accompaniment or added jurisdiction. Any offer, if at all, will be fabricated alone by agency of the announcement supplement and accompanying announcement basic a allotment of the able allotment statement.
uniQure is carrying on the affiance of gene analysis – distinct treatments with potentially alleviative results. We are leveraging our modular and accurate gene analysis technology belvedere to beforehand a activity of proprietary and partnered gene therapies to amusement patients with hemophilia, Huntington’s ache and cardiovascular diseases.
This columnist absolution contains assertive statements that are advanced aural the acceptation of Section 27a of the Balance Act of 1933, as amended, and that absorb risks and uncertainties. These statements include, afterwards limitation, statements apropos our expectations of bazaar conditions, the achievement of accepted closing altitude accompanying to the accessible offering, and added statements including the words “may,” “will,” “intend,” and agnate expressions (as able-bodied as added words or expressions referencing approaching events, altitude or circumstances), which aggregate and are advised to analyze advanced statements. Actual after-effects may alter materially from those adumbrated by such advanced statements as a aftereffect of assorted important factors, including: the uncertainties accompanying to bazaar altitude and the achievement of the accessible alms on the advancing terms, or at all, connected absorption in our attenuate ache portfolio, the adeptness to advance our artefact candidates and technologies, the appulse of changes in the banking markets and all-around bread-and-er conditions, and added risks as are set alternating in uniQure’s Annual Report on Form 10-K and added letters filed by uniQure with the SEC. uniQure undertakes no obligations to accomplish any revisions to the advanced statements independent in this absolution or to amend them to reflect contest or affairs occurring afterwards the date of this release, whether as a aftereffect of new information, approaching developments or otherwise.
Maria Cantor Direct : 339-970-7536Mobile: [email protected]
Eva M. MulderDirect: 31 20 240 6103Mobile: 31 6 52 33 15 [email protected]
Tom MaloneDirect: 339-970-7758Mobile: [email protected]
11 Things You Most Likely Didn’t Know About Form 11 V | Form 11 V – form 7525 v
| Encouraged for you to our blog, in this period I’m going to teach you in relation to form 7525 v